Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Alzheimer Disease
Interventions
DRUG

bapineuzumab

5 mg/week subcutaneous bapineuzumab

Trial Locations (16)

14620

Monroe Community Hospital, Rochester

30033

Neurostudies.net, Decatur

30045

Dekalb Neurology Associates, LLC, Lawrenceville

30046

NeuroStudies.net, Lawrenceville

33009

MD Clinical, Hallandale

33407

Palm Beach Neurology - Premiere Research Institute, West Palm Beach

33445

Brain Matters Research, Delray Beach

53705

University of Wisconsin, Department of Surgery, Madison

53792

University of Wisconsin, Madison

67207

Clinical Research Institute, Wichita

75214

Texas Neurology, P.A., Dallas

85006

Banner Alzheimer's Institute, Phoenix

91316

Pharmacology Research Institute, Encino

02914

Rhode Island Mood and Memory Research Institute, East Providence

02906

Butler Hospital, Providence

05201

The Memory Clinic, Bennington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

INDUSTRY

lead

Pfizer

INDUSTRY